Drug intelligence / Profile preview

MB-siCOV

Development stage: Preclinical
Lead developer: Mercury Bio
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

MB-siCOV is a preclinical small interfering RNA (siRNA) therapeutic developed by Mercury Bio (Mercury Holdings) for the treatment of COVID-19. The drug is designed to silence specific SARS-CoV-2 viral genes through the RNA interference (RNAi) pathway, effectively preventing viral replication and assembly. Mercury Bio utilizes a proprietary delivery platform for the intracellular delivery of nucleic acids, and MB-siCOV represents their antiviral application of this technology to target the SARS-CoV-2 genome. The program is currently in the preclinical stage of development.

Targets

SARS-CoV-2 gRNA (SARS-CoV-2 genomic RNA)

Beyond the preview

Go deeper on MB-siCOV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MB-siCOV.

Explore the full profile